48 results found.

Influenza A Clinical Trial using Anti-Influenza Plasma; Standard Care

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting N/A or older.
- A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza A Immune Plasma for the Treatment of Influenza A (IRC002).
Anti-Influenza Plasma; Standard Care

Influenza Clinical Trial using Ergoferon; Oseltamivir(Tamiflu)

Materia Medica Holding - Recruiting 18 years to 60 years.
- Multicentre Open Label Comparative Parallel-group Randomized Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza.
Ergoferon; Oseltamivir(Tamiflu)

Influenza Virus Clinical Trial using Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)

Novartis - Recruiting 6 Months to 72 Months.
- A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ò6 to < 72 Months of Age..
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)

Influenza Clinical Trial using favipiravir

MDVI, LLC - Recruiting 18 years to 80 years.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza.
favipiravir

Influenza Clinical Trial using CT-P27; Placebo

Celltrion - Recruiting 18 years to 45 years.
- A Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model.
CT-P27; Placebo

Influenza, or Flu Clinical Trial using Anti-influenza IVIG

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects.
Anti-influenza IVIG

Influenza A Clinical Trial using Vaccine FP-01.1; Placebo; Virus Challenge

Immune Targeting Systems Ltd - Recruiting 18 years to 45 years.
- A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (Vaccine FP-01.1) in Healthy Volunteers Following Virus Challenge.
Vaccine FP-01.1; Placebo; Virus Challenge

Influenza, Human Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Screening of Volunteers for Influenza Human Challenge Studies.

Influenza, or Healthy Clinical Trial using H5N1 vaccine plus MF59 adjuvant; H5N1 vaccine without adjuvant

National Institutes of Health Clinical Center (CC) - Recruiting 21 years to 45 years.
- Characterization of Innate Immune Responses to MF59 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine.
H5N1 vaccine plus MF59 adjuvant; H5N1 vaccine without adjuvant

Influenza Clinical Trial using AVI-7100 versus placebo

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects.
AVI-7100 versus placebo

H5N1 Influenza Clinical Trial using Ad4-H5-VTN vaccination-tonsillar route; Ad4-H5-vaccination-oral route

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 49 years.
- Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers.
Ad4-H5-VTN vaccination-tonsillar route; Ad4-H5-vaccination-oral route

Influenza A, Influenza B, or RSV Clinical Trial

IQuum, Inc. - Recruiting N/A or older.
- Multi-Center Study of In Vitro Diagnostic Devices for the Detection of Influenza A, Influenza B, and RSV.

Influenza Clinical Trial using MG1109

Green Cross Corporation - Recruiting 18 years to 60 years.
- Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers.
MG1109

Atrial Fibrillation Clinical Trial using `MyDiagnostick

UMC Utrecht - Recruiting N/A or older.
- Screening for Silent Atrial Fibrillation During Influenza Vaccination.
`MyDiagnostick

Influenza Clinical Trial using oseltamivir [Tamiflu]

Hoffmann-La Roche - Recruiting N/A to 12 years.
- AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLUr) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMISED CHILDREN, FROM 2 WEEKS TO LESS THAN 13 YEARS OF AGE, WITH CONFIRMED INFLUENZA INFECTION.
oseltamivir [Tamiflu]

Influenza, Human Clinical Trial using 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; 75mg oral oseltamivir and intravenous zanamivir placebo

GlaxoSmithKline - Recruiting 16 years or older.
- A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza.
300mg intravenous (IV) zanamivir and oral oseltamivir placebo; 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; 75mg oral oseltamivir and intravenous zanamivir placebo

Hepatitis A Clinical Trial using Influenza vaccine GSK2321138A; Havrix Junior; Wyeth Prevenar; Sanofi Pasteur Varivax/ProVarivax; Varilrix

GlaxoSmithKline - Recruiting 6 Months to 35 Months.
- An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children.
Influenza vaccine GSK2321138A; Havrix Junior; Wyeth Prevenar; Sanofi Pasteur Varivax/ProVarivax; Varilrix

Influenza Clinical Trial using favipiravir; Placebo

MDVI, LLC - Recruiting 18 years to 80 years.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza (T705US316).
favipiravir; Placebo

Influenza Clinical Trial using Amantadine, Ribavirin, Oseltamivir; Oseltamivir

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years or older.
- A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications.
Amantadine, Ribavirin, Oseltamivir; Oseltamivir

Influenza Clinical Trial using Atorvastatin; Placebo

Beth Israel Deaconess Medical Center - Recruiting 18 years or older.
- Statin Therapy in Acute Influenza.
Atorvastatin; Placebo

Influenza Clinical Trial using oseltamivir

Hoffmann-La Roche - Recruiting 1 year or older.
- A Double-blind, Randomized, Stratified Multi-center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza.
oseltamivir

Healthy Volunteer Clinical Trial using MHAA549A; Placebo; oseltamivir [Tamiflu]

Genentech - Recruiting 18 years to 45 years.
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study in Healthy Volunteers to Evaluate the Efficacy and Safety of MHAA4549A in an Influenza Challenge Model.
MHAA549A; Placebo; oseltamivir [Tamiflu]

Influenza, Human Clinical Trial using Oseltamivir; Oseltamivir Placebo

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 64 years.
- A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults.
Oseltamivir; Oseltamivir Placebo

Influenza Clinical Trial using GSK1557484A vaccine

GlaxoSmithKline - Recruiting 18 years or older.
- Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure.
GSK1557484A vaccine

Influenza Clinical Trial using TIV

Novartis - Recruiting 6 Months to 4 years.
- A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age..
TIV

Influenza, Human Clinical Trial using Virus administration

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Evaluation of Anti-Hemagglutinin Antibodies as a Correlate of Protection in an H1N1 Influenza Healthy Human Challenge Model.
Virus administration

Breast Cancer, Colon Cancer, or Bladder Cancer Clinical Trial using Glycosylated Recombinant Human Interleukin-7; Diphtheria-Tetanus Vaccine; Polio Vaccine; Pneumaococcal Vaccine; Hepatitis A Vaccine; Hepatitis B Vaccine; Influenza Vaccine; PhiX 174

National Institutes of Health Clinical Center (CC) - Recruiting 60 years or older.
- A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy.
Glycosylated Recombinant Human Interleukin-7; Diphtheria-Tetanus Vaccine; Polio Vaccine; Pneumaococcal Vaccine; Hepatitis A Vaccine; Hepatitis B Vaccine; Influenza Vaccine; PhiX 174

Herpesvirus, Adenovirus, Cytomegalovirus, Human Papillomavirus, H Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- The Natural History of Severe Viral Infections and Characterization of Immune Defects.

Hepatitis B Clinical Trial

National University Hospital, Singapore - Recruiting 21 years to 45 years.
- Antigen-specific Immune Response to Hepatitis B Virus and Influenza A (H1N1 Strain) in Utero.

Clinically Suspected H1N1 Infection Clinical Trial

Medical University of Graz - Recruiting N/A or older.
- Influenza A H1N1: Retrospective Analysis of PCR Confirmed Cases of H1N1 Infections in Styria - Risk Factors, Clinical Features and Outcome. Development of a Clinical Score for Suspected H1N1 Infection..

Hepatitis, or Hepatitis C Clinical Trial using Algeron; Pegasys

Biocad - Recruiting 18 years to 70 years.
- An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C.
Algeron; Pegasys

Influenza Clinical Trial using Intravenous hyperimmune immunoglobulin (IVIG)

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years or older.
- Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study(Flu-IVIG Pilot).
Intravenous hyperimmune immunoglobulin (IVIG)

Influenza Clinical Trial using Rapid Influenza Testing with Xpert Flu

Johns Hopkins University - Recruiting 18 years or older.
- Influenza Diagnosis, Treatment and Surveillance With Xpert Flu.
Rapid Influenza Testing with Xpert Flu

Influenza Clinical Trial using CR8020; CR6261; Placebo

Crucell Holland BV - Recruiting 18 years or older.
- Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of CR8020 and CR6261 in Hospitalized Patients With Influenza A Infection.
CR8020; CR6261; Placebo

Influenza Type A, or Influenza Type B Clinical Trial using Nasopharyngeal Swab

St. Jude Children's Research Hospital - Recruiting N/A to 18 years.
- Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China.
Nasopharyngeal Swab

Egg Hypersensitivity Clinical Trial using Administration of Live attenuated influenza vaccine

Imperial College London - Recruiting 2 years to 17 years.
- Phase 4 Study to Assess the Safety of Nasal Influenza Immunisation in Egg Allergic Children - a Multicentre Observational Study.
Administration of Live attenuated influenza vaccine

Influenza Vaccine Effectiveness Clinical Trial

MedImmune LLC - Recruiting 2 years to 17 years.
- A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age.

Influenza, Infectious Disease, or Pregnancy Clinical Trial using Influenza Vaccine Intervention

The University of Hong Kong - Recruiting 18 years or older.
- A Randomized Controlled Trial of a Brief Educational Intervention to Increase Uptake of Influenza Vaccine Among Pregnant Women.
Influenza Vaccine Intervention

Influenza Clinical Trial using LAIV H2N2; Placebo

Program for Appropriate Technology in Health - Recruiting 18 years to 40 years.
- Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/California/66/395 (H2N2)Influenza Vaccine.
LAIV H2N2; Placebo

Influenza Infection Clinical Trial using green tea

University of Shizuoka - Recruiting 15 years to 20 years.
- Effects of Gargling With Green Tea on Preventing Influenza Infection Among High School Students: A Randomized Clinical Study.
green tea

Influenza Virus Infection Transmission in Humans Clinical Trial

University of Maryland - Recruiting 10 years or older.
- Evaluating Modes of Influenza Transmission Work Package 1: Observational Study of Community Acquired Influenza.

Influenza Clinical Trial

Fraser Health - Recruiting 65 years or older.
- A Case-Control Study to Evaluate the Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine in the Elderly Aged ò65 Years..

Pandemic Influenza Clinical Trial using Pandemic Influenza Vaccine (H5N1)

Adimmune Corporation - Recruiting 20 years to 60 years.
- A Clinical Study to Evaluate the Immunogenicity and Safety of Pandemic Influenza Vaccine, AdimFlu-W (H5N1), in Healthy Adults.
Pandemic Influenza Vaccine (H5N1)

Influenza Clinical Trial using Influenza Virus Vaccine (no Preservative ); Influenza Virus Vaccine(contains Preservative)

Chinese Academy of Medical Sciences - Recruiting 36 Months or older.
- The Phase ? Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated).
Influenza Virus Vaccine (no Preservative ); Influenza Virus Vaccine(contains Preservative)

Influenza Clinical Trial

Dalhousie University - Recruiting 16 years or older.
- Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults.

Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, or Congenit Clinical Trial using 2011-2012 seasonal flu vaccine

Children's Hospital Medical Center, Cincinnati - Recruiting 3 years to 35 years.
- Comparison of the Immunogenicity of Intramuscular Versus Subcutaneous Administration of Trivalent Inactivated Influenza Vaccine in Individuals With Neuromuscular Diseases.
2011-2012 seasonal flu vaccine

Organ Transplantation Clinical Trial

Sahlgrenska University Hospital, Sweden - Recruiting 18 years to 80 years.
- Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients..